EP 225: Dr. Spencer Nadolsky On The Truth About GLP-1’s, Weight Loss, and Strength Training

In this in-depth episode of the Vigor Life Podcast, host Luca engages with Dr. Spencer Nadolsky, a leading expert in metabolic health and GLP-1 therapies, to unpack the truth behind the widespread use of weight-loss drugs like Ozempic, Wegovy, and Zepbound. Dr. Nadolsky provides a clinical framework for who should and shouldn’t take these medications, emphasizing that while originally approved for type 2 diabetes, their use for obesity has expanded—now based on clinical diagnosis rather than BMI alone. He challenges the myth that GLP-1s cause muscle loss or bone density decline, explaining that these side effects are more related to calorie restriction than the drugs themselves, and that resistance training is key to preserving lean mass. The conversation dives into the psychological stigma around obesity, the danger of using these drugs purely for vanity, and the importance of integrating strength training, nutrition, and mental health support. Dr. Nadolsky also addresses the growing use of unregulated peptides like BPC-157 and the experimental RETA triple agonist, urging caution due to lack of FDA approval and potential risks. He stresses ethical responsibility for coaches and clinicians, warning against kickbacks and promoting evidence-based, patient-centered care. The episode concludes with practical advice on dosing, tapering, and long-term management of GLP-1 therapy, reinforcing that these drugs are tools—not magic solutions—and should be part of a holistic health strategy.